Catalyst Pharmaceutical Partners shares owned by Rhumbline Advisers
Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Rhumbline Advisers
from 13F filings
Historical chart of Rhumbline Advisers investment in Catalyst Pharmaceutical Partners
Tip: Access up to 7 years of quarterly data
All positions including Catalyst Pharmaceutical Partners held by Rhumbline Advisers consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Catalyst Pharmaceutical Partners by Rhumbline Advisers
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2024-12-31 | $6.5M | 312k | 20.87 |
| 2024-09-30 | $6.2M | 311k | 19.88 |
| 2024-06-30 | $5.0M | 324k | 15.49 |
| 2024-03-31 | $5.0M | 313k | 15.94 |
| 2023-12-31 | $4.9M | 289k | 16.81 |
| 2023-09-30 | $3.4M | 292k | 11.69 |
| 2023-06-30 | $3.9M | 288k | 13.44 |
| 2023-03-31 | $4.7M | 281k | 16.58 |
| 2022-12-31 | $4.9M | 264k | 18.60 |
| 2022-09-30 | $3.3M | 258k | 12.83 |
| 2022-06-30 | $777k | 111k | 7.01 |
| 2022-03-31 | $1.1M | 128k | 8.29 |
| 2021-12-31 | $1.0M | 149k | 6.77 |
| 2021-09-30 | $793k | 150k | 5.30 |
| 2021-06-30 | $847k | 147k | 5.75 |
| 2021-03-31 | $551k | 120k | 4.61 |
| 2020-12-31 | $422k | 126k | 3.34 |
| 2020-09-30 | $354k | 119k | 2.97 |
| 2020-06-30 | $628k | 136k | 4.62 |
| 2020-03-31 | $486k | 126k | 3.85 |
| 2019-12-31 | $473k | 126k | 3.75 |
| 2019-09-30 | $666k | 125k | 5.31 |
| 2019-06-30 | $485k | 126k | 3.84 |
| 2019-03-31 | $629k | 123k | 5.10 |
| 2018-12-31 | $243k | 127k | 1.92 |
| 2018-09-30 | $319k | 85k | 3.78 |
| 2018-06-30 | $283k | 91k | 3.12 |
| 2018-03-31 | $161k | 67k | 2.39 |
| 2017-12-31 | $244k | 63k | 3.90 |
| 2017-09-30 | $194k | 77k | 2.53 |
| 2017-06-30 | $209k | 76k | 2.76 |
| 2016-03-31 | $90k | 77k | 1.17 |
| 2015-12-31 | $184k | 75k | 2.45 |
| 2015-09-30 | $206k | 69k | 3.01 |
| 2015-06-30 | $267k | 65k | 4.12 |
Top funds holding Catalyst Pharmaceutical Partners
View all funds holding Catalyst Pharmaceutical Partners